Ποια είναι η τιμή για AcelRx Pharmaceuticals, Inc. (ACRX)

Η τιμή για AcelRx Pharmaceuticals, Inc. (ACRX) είναι $0.922

Ποια είναι η κεφαλαιοποίηση αγοράς για AcelRx Pharmaceuticals, Inc. (ACRX)

Η κεφαλαιοποίηση αγοράς για AcelRx Pharmaceuticals, Inc. (ACRX) είναι $11.68M

AcelRx Pharmaceuticals, Inc. (ACRX) Τιμή και Κεφαλαιοποίηση Αγοράς

AcelRx Pharmaceuticals, Inc. is a specialized biopharmaceutical firm primarily dedicated to advancing and bringing to market medical solutions for managing acute pain. The company's key commercial products include DSUVIA and DZUVEO, which are 30 microgram sufentanil tablets administered under the tongue, intended for treating significant short-term pain. AcelRx also develops ZALVISO, a pre-programmed, patient-managed analgesia system that enables hospital patients experiencing moderate-to-severe acute pain to self-administer sufentanil sublingual tablets for their pain relief. In its development pipeline, AcelRx is progressing ARX-02, which is currently in Phase 2 clinical trials, targeting sudden, intense cancer-related pain in individuals who are tolerant to opioid medications. Another candidate, 4ARX-03, is being investigated for its utility in providing mild sedation and pain relief during various medical procedures that might cause discomfort. Beyond acute pain, AcelRx's investigational portfolio features Niyad, a regional anticoagulant designed for use in external blood circulation systems. Furthermore, LTX-608, a nafamostat formulation for direct intravenous infusion, is being explored as an experimental treatment for a range of conditions, including COVID, severe lung injury (acute respiratory distress syndrome), widespread blood clotting (disseminated intravascular coagulation), and acute pancreatitis. The company was founded in 2005 and initially operated under the name SuRx, Inc., before officially rebranding as AcelRx Pharmaceuticals, Inc. in August 2006. It is headquartered in Hayward, California.

Η τιμή για ACRX	Το περιουσιακό στοιχείο B	Η κεφαλαιοποίηση αγοράς του B	Αποτελέσματα
$430,882 $11.68M	NVDA	$5.460T	+46,733,332.59%
$354,284 $11.68M	AAPL	$4.489T	+38,425,473.08%
$326,775 $11.68M	GOOG	$4.141T	+35,441,860.92%
$281,608 $11.68M	MSFT	$3.569T	+30,543,043.11%
$220,804 $11.68M	AMZN	$2.798T	+23,948,281.60%

Η τιμή για ACRX

Το περιουσιακό στοιχείο B

Η κεφαλαιοποίηση αγοράς του B

Αποτελέσματα

$430,882 $11.68M